Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Griet Hoste,Laurence Slembrouck,Lynn Jongen,Kevin Punie,Tom Matton,Sara Vander Borght,Isabelle Vanden Bempt,Johan Menten,Hans Wildiers,Giuseppe Floris,Carlos L Arteaga,Patrick Neven

Clinical Drug Investigation（2019）

引用 0|浏览31

暂无评分

摘要

Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要